I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.
Education and Training
- Fellowship, Hematology Oncology, Duke University School of Medicine, 2011 - 2014
- Residency, Osler Medical Housestaff Training Program, Johns Hopkins University School of Medicine, 2008 - 2011
- M.D., Harvard University , 2008
- Protocol Number CA209920
- Mitigators of Radiation-Induced Endovascular Injury: Targeting Tie2 and Thrombocytopenia
- Patient-centered home-based hematopoietic stem cell transplantation
- Prevention of Gastrointestinal Toxicity from total body irradation or high dose Chemo with SOM230
- Effects of In-Home Hematopoietic Stem Cell Transplantation on the Gut Microbiota.
- AZD9668 and Neutrophil Elastase Inhibition to Prevent Graft-versus-Host Disease
- Personalized Prebiotics to Optimize Microbiota Metabolism and Improve Transplant Outcomes
- Duke CTSA (KL2)